Skip to main content

Table 2 BPRS total score and 5-factor model scores from the baseline to 12 weeks after initiation of treatment

From: Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance

BPRS (mean ± SD)

Baseline (N = 392)

2/4 weeks (N = 384)

6/8 weeks (N = 345)

12 weeks (N = 311)

Total Score

48.8 ± 14.1

36.8 ± 11.0**

30.6 ± 9.6**

25.5 ± 7.6**

Anxiety-depression

10.0 ± 3.5

8.1 ± 2.9**

7.0 ± 2.6**

5.9 ± 2.1**

Anergia

9.9 ± 3.5

7.9 ± 2.8**

6.7 ± 2.3**

5.9 ± 2.1**

Thought disturbance

11.9 ± 4.5

8.8 ± 3.6**

7.2 ± 3.2**

5.8 ± 2.3**

Activation

6.9 ± 3.2

5.0 ± 2.2**

4.2 ± 1.8**

3.7 ± 1.3**

Hostility-suspiciousness

10.1 ± 4.1

6.9 ± 3.0**

5.5 ± 2.5**

4.3 ± 1.8**

  1. ** P < 0.001, BPRS = Brief Psychiatric Rating Scale